

**NOW ENROLLING**

**CRN00808-11**

# **Phase 2 Investigational Once-Daily Oral Study Drug for Patients with Carcinoid Syndrome associated with Neuroendocrine Tumors (NETs)**

## **About** the study

Study centers are enrolling participants for a Phase 2 clinical study evaluating the safety and potential effects of paltusotine, an investigational once-daily oral drug for patients with carcinoid syndrome associated with NETs. Paltusotine is an investigational drug which means that it has not been approved by any regulatory authority.

## What will **The Study** involve?

- ✓ This study includes a Screening Period and a Treatment Period. The Screening Period is from 2 to 12 weeks.
- ✓ There is an 8-week Treatment Period with an optional 50-week extension.
- ✓ You will take the study drug once a day, by mouth, each morning. All participants will receive paltusotine in place of their current treatment.
- ✓ You will be asked to complete a daily electronic symptom diary (eDiary) provided by your study doctor.
- ✓ Qualified participants may receive the study drug and study-related care at no cost.

## **Who** may qualify?

18+ years old

Confirmed NETs and carcinoid syndrome

Currently treated with octreotide or lanreotide **OR** not treated with octreotide or lanreotide and with active symptoms

Other eligibility criteria will apply.



SCAN ME

For more information,  
scan this QR code to visit [lacnets.carcinoidstudy.com](http://lacnets.carcinoidstudy.com)